Читать книгу Tendencias en Investigación Clínica - Galo Peralta Fernández - Страница 42

– Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, et al. Signatures of mutational processes in human cancer. Nature 2013;500:415-21.

– Cocco E, Schram AM, Kulick A, Misale S, Won HH, Yaeger R, et al. Resistance to TRK inhibition mediated by convergent MAPK pathway activation. Nat Med 2019;25:1422-7.

– Elizabeth H. Blackburn Cancer Interception. Cancer Prev Res; 4(6); 787-92.2011.

– Kang SP, Gergich K, Lubiniecki GM et al. Pembrolizumab KEYNOTE-001: an adaptive study leading to accelerated approval for two indications and a companion diagnostic. Ann Oncol. 2017 Jun 1;28(6):1388-1398.

– Pazdur R. The seamless approach to drug development in oncology. Clin Adv Hematol Oncol 2016; 14:958-9.

– The Future of Clinical Trial Design in Oncology. Spreafico A et al. Cancer Discov 2021;11:822-37.